After reviewing outcomes from Canadian research communities, I believe accelerated protocols get oversold online
Paired with a published Certificate of Analysis, that makes the provenance of each dose far easier to defend
The cardioprotective effects of GLP-1RAs include anti-inflammatory actions, reduction of myocardial ischemia injury, modifications in the synthesis and secretion of lipids, and improvement of endothelial dysfunction (109)
Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Primary Outcomes: Percentage change in body weight
This could reflect a legal-entity change over time, a U.S
